

Date: _____

Facility Contact:	Phone #:	Ext.:	Facility Fax #:
Facility Name:	# of Fridges: _____ Type: <input type="checkbox"/> Bar <input type="checkbox"/> Domestic <input type="checkbox"/> Purpose Built		
• Place orders by Wednesday 3 pm for pick up the following Wednesday		• Coolers must be between 2 - 8 °C for vaccine to be released	
• Orders must include the previous 4 week temperature log for all fridges		• Vaccine order inquiries ext. 8808	

➤ REFER to the [PUBLICLY FUNDED IMMUNIZATION SCHEDULES FOR ONTARIO \(June 2022\)](#) for # of eligible doses and intervals between doses (product specific tables noted below).

➤ REFER to the [Guidance for Routine & Catch-Up Immunization Services \(Version 5 – Jan 2024\)](#) for temporary program extensions for 2024.

Initials (First. Last): _____ DOB (YYYY/MM/DD): _____

Vaccine Name	Product / Description	Dose # in Series Requested	Eligibility Criteria (<u>check all that apply</u>)
Bexsero®	Meningococcal B (4CMenB)	Dose: <input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4 (See Table 14)	Age 2 months through 17 years*: <input type="checkbox"/> Functional or anatomic asplenia <input type="checkbox"/> Complement, properdin, factor D deficiency, or primary antibody deficiency <input type="checkbox"/> Cochlear implant recipient (pre/post implant) <input type="checkbox"/> Acquired complement deficiency (e.g., receiving eculizumab) <input type="checkbox"/> HIV <i>*Temporary extension for individuals born in 2002, 2003, 2004, 2005 and 2006 – remain eligible for missed doses until Dec 31, 2024</i>
		Dose: <input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4 <input type="checkbox"/> Booster (See Table 15)	Age 9 months through 55 years: <input type="checkbox"/> Functional or anatomic asplenia <input type="checkbox"/> Complement, properdin, factor D deficiency or primary antibody deficiency <input type="checkbox"/> Cochlear implant recipient (pre/post implant) <input type="checkbox"/> Acquired complement deficiency (e.g., receiving eculizumab) <input type="checkbox"/> HIV
Nimenrix® Menactra®	Meningococcal C-ACYW135	Dose: <input type="checkbox"/> 1 <input type="checkbox"/> 2** **only if born in 1964, 1965, 1966) (See Table 15)	Age ≥ 56 years*: <input type="checkbox"/> Functional or anatomic asplenia <input type="checkbox"/> Complement, properdin, factor D deficiency or primary antibody deficiency <input type="checkbox"/> Cochlear implant recipients (pre/post implant) <input type="checkbox"/> Acquired complement deficiency (e.g., receiving eculizumab) <input type="checkbox"/> HIV <i>*Temporary extension for individuals born in 1964, 1965, 1966, 1967 and 1968 – remain eligible for missed doses until Dec 31, 2024.</i>

Location to be picked up (please check):

Gravenhurst Huntsville Orillia

VIM Order # (for office use only): _____

Confidentiality Notice:

The contents of the document(s) accompanying this facsimile transmission are confidential and intended only for use by the individual(s) named above. It may contain information that is privileged, confidential, or otherwise protected from disclosure. Any review, dissemination or use of this transmission or its contents by persons other than the addressee is strictly prohibited.

Vaccine Name	Product / Description	Dose # in Series Requested	Eligibility Criteria <i>(check all that apply)</i>
Avaxim® / Havrix® / Vaqta® Avaxim® Pediatric Havrix® Pediatric Vaqta® Pediatric	Hepatitis A	Dose: <input type="checkbox"/> 1 <input type="checkbox"/> 2 <i>(See Table 5)</i>	Age ≥ 1 year: <input type="checkbox"/> Chronic liver disease (including hepatitis B and C) <input type="checkbox"/> Persons engaging in intravenous drug use <input type="checkbox"/> Men who have sex with men
Recombivax HB® / Engerix-B® Recombivax HB® Pediatric Engerix-B® Pediatric	Hepatitis B <input type="checkbox"/> Latex allergy	Dose: <input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4 <i>(See Table 7)</i>	Age ≥ 0 years: <input type="checkbox"/> Infant born to HBV-positive mothers: <ul style="list-style-type: none"> ○ Premature infant weighing < 2,000 grams at birth (4 doses) ○ Premature infant weighing ≥ 2000 grams at birth and full/post terms infants (3 doses) <input type="checkbox"/> Household or sexual contact of chronic carrier or acute cases (3 doses) <input type="checkbox"/> Individual engaging in intravenous drug use (3 doses) <input type="checkbox"/> Men who have sex with men, individual with multiple sex partners or history of sexually transmitted disease (3 doses) <input type="checkbox"/> Needle stick injury in a non-health care setting (3 doses) <input type="checkbox"/> Child < 7 years old whose family has immigrated from country of high prevalence for hepatitis B and who may be exposed to hepatitis B carriers through their extended family (3 doses) <input type="checkbox"/> Chronic liver disease including hepatitis C (3 doses) <input type="checkbox"/> Awaiting liver transplant (2 nd and 3 rd dose only)
High Dose (Dialysis) Formulation Recombivax HB®	Hepatitis B	Dose: <input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <i>(See Table 7)</i>	Age ≥ 20 years: <input type="checkbox"/> Chronic renal disease or on dialysis <input type="checkbox"/> Chronic liver disease <input type="checkbox"/> Individuals awaiting liver transplant <input type="checkbox"/> HIV
Gardasil®	HPV-9	Dose: <input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <i>(Table 10 and Table 11)</i>	Males 9 to 26 years*: <input type="checkbox"/> Men who have sex with men <i>*Temporary extension for males born in 1993, 1994, 1995, 1996, and 1997 – remain eligible for missed doses until Dec 31, 2024.</i>

Location to be picked up (please check):

Gravenhurst Huntsville Orillia

VIM Order # (for office use only): _____

2024-01-25

Confidentiality Notice:

The contents of the document(s) accompanying this facsimile transmission are confidential and intended only for use by the individual(s) named above. It may contain information that is privileged, confidential, or otherwise protected from disclosure. Any review, dissemination or use of this transmission or its contents by persons other than the addressee is strictly prohibited.